cardiology update - infomed research & training limited · cardiology update 11th update for...
TRANSCRIPT
![Page 1: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/1.jpg)
Cardiology Update
11th Update for the General Anaesthetist, June 2017
1
Daniel Bromage
NIHR Clinical Lecturer & Specialty Trainee in Cardiology
![Page 2: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/2.jpg)
Overview
• Acute coronary syndromes & PCI
• Antiplatelet agents
• Pacemakers and peri-operative management
• Atrial fibrillation and stroke prevention
• OOHCA without ST elevation
• What’s new in heart failure?
2
![Page 3: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/3.jpg)
ACUTE CORONARY SYNDROMES & PCI
3
Unstable angina(UA)
ST-segment elevation myocardial infarction
(STEMI)
Non-ST-segment myocardial infarction
(NSTEMI)
Collectively known as NSTE-ACS
![Page 4: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/4.jpg)
![Page 5: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/5.jpg)
7.5
12.1
14.8
0
5
10
15
20
Mortality for ACS
GRACE study (n = 1143)
Mortality doubles within 1 year of discharge from
hospital
In-hospital 6-months 1-year
Mo
rtality
rate
(%
)
Tang EW, et al. Am Heart J 2007;153(1):29-355
![Page 6: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/6.jpg)
Patterns of healing
6In-stent restenosis Acute stent thrombosis?
![Page 7: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/7.jpg)
Drug eluting stents
7Bromage DI, et al. Heart 2012;98(Suppl1):A24
![Page 8: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/8.jpg)
Platform design
8
First-generation DES Newer-generation DES
![Page 9: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/9.jpg)
Stent struts
Thrombus
C
Images provided by Dr N West, Papworth Hospital, Cambridge9
![Page 10: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/10.jpg)
Stent thrombosis
• Uncommon but high mortality (10-40%)
• Mostly in the first month (60%), but even up to 5 years!
• 1.5-2% at 2 years
• Newer-generation DES have a lower risk of stent thrombosis
10Sarno G, et al. JACC. 2014;64:16-24
![Page 11: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/11.jpg)
Risks for stent thrombosis
Procedural factors
• Under-sizing (OR 13.5)
• Dissection (OR 6)
• Poor TIMI flow post PCI (OR 5)
• Long/narrow stents
• Complex procedure/extensive disease
• Acute coronary syndrome
Patient factors
• LVEF <30% (OR 2.7)
• DM
• Renal disease
• Malignancy
Inadequate anti-platelet treatment
• Premature discontinuation of P2Y12 inhibitors (OR 36.5!)
• Resistance to clopidogrel i.e. CYP2C19 status, ?omeprazole use11
![Page 12: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/12.jpg)
Bioresorbable vascular scaffolds
12Lancet. 2016;388:2479
![Page 13: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/13.jpg)
ANTI-PLATELET AGENTS
13
20091998 20111991 2000’s
PrasugrelClopidogrelAspirin Ticlopidine(not available in the UK)
Dual anti-platelet therapy
1980s
![Page 14: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/14.jpg)
TRITON-TIMI 38: Primary endpoint
Days
% o
f P
atie
nts
0
5
10
15
0 30 60 90 180 270 360 450
HR: 0.81(0.73-0.90)P<.001
Prasugrel (n=6813)
Clopidogrel (n=6795)
12.1%
9.9%
NNT=46
Wiviott SD, et al. N Engl J Med. 2007;357(20):2001-2015
CV Death/MI/Stroke at 15 months
14
![Page 15: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/15.jpg)
TRITON-TIMI 38: Stent thrombosis
2.4
1.1
0
2
4
Prasugrel
(n=6813)
Clopidogrel
(n=6795)
% o
f P
atie
nts
P<.001
Wiviott SD, et al. N Engl J Med. 2007;357(20):2001-201515
![Page 16: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/16.jpg)
TRITON-TIMI 38: Safety
1.8
0.9 0.9
0.1
3.0
2.4
1.41.1
0.4
4.0
0
2
4
6
TIMI MajorBleeds
LifeThreatening
Nonfatal Fatal Transfusion
Clopidogrel (n=6795)
Prasugrel (n=6813)
% E
ven
ts
*Most frequent sites of life-threatening bleeding: Gastrointestinal, intracranial, puncture, and retroperitoneal.
Wiviott SD, et al. N Engl J Med. 2007;357(20):2001-2015
P=.03
P=.01 P=.23
P=.002
P<.001
*
16
![Page 17: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/17.jpg)
P2Y12 characteristics
Characteristics Clopidogrel1,2 Prasugrel1,3 Ticagrelor1,4
Direct acting
Reversible binding to P2Y12
receptor
Rapid onset of action
> 60% IPA (mean steady state)
More consistent response
1. Wallentin L. Eur Heart J 2009;30:1964-1977; 2. Clopidogrel. Summary of product characteristics 2010; 3. Prasugrel. Summary of product characteristics 2009; 4. Ticagrelor.
Summary of product characteristics 2010 17
![Page 18: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/18.jpg)
Ticagrelor
• Direct acting
• Reversibly binds toP2Y12 receptor
Ticagrelor is aCyclo-pentyl-triazolo-pyrimidine (CPTP)
Husted S, et al. Eur Heart J 2006;27:1038-1047 18
![Page 19: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/19.jpg)
Ticagrelor is not a prodrug
No in vivobiotransformation
needed
Prasugrel
Active metabolite
Clopidogrel
Active metabolite
85%
inactive
metabolite1
Prodrug
Hydrolysis
(Esterases)
CYP-dependant
oxidation
CYP-dependant
oxidation
Intermediary metabolite
Intermediary metabolite
Ticagrelor
Figure adapted from: Schomig AS. N Eng J Med 2009;36:1108-1111.
1. Clopidogrel. Summary of product characteristics. 2010 19
![Page 20: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/20.jpg)
Ticagrelor onset and efficacy
0
25
50
75
100
0.5 2 4 8
Ticagrelor Clopidogrel
Time post-loading dose (hours)
In
hib
itio
n o
f p
late
let
ag
gre
ga
tio
n (
%)
Patients with stable CAD, which is not a licensed population for ticagreloruse
* p < 0.0001, ticagrelor vsclopidogrel
*
* **
Adapted from: Gurbel PA, et al. Circulation 2009;120:2577-258520
![Page 21: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/21.jpg)
Ticagrelor reduces MACE
Kaplan-Meier estimate of time to primary endpoint (composite of CV death, MI or stroke)
No. at risk
Ticagrelor 9,333 8,628 8,460 6,743 5,161
Clopidogrel 9,291 8,521 8,362 8,124 6,743 5,096 4,047
4,1478,219
Days after randomisation
0 60 120 180 240 300 360
12
11
10
9
8
7
6
5
4
3
2
1
0
13
Cu
mu
lati
ve
in
cid
en
ce
(%
)
9.8
11.7
HR 0.84 (95% CI 0.77–0.92), p=0.0003
Clopidogrel
Ticagrelor
RRR = 16%ARR = 1.9%NNT = 54
Wallentin L, et al. N Engl J Med 2009;361:1045-1057
All patients received aspirin (75-100 mg/d)
21
![Page 22: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/22.jpg)
0.3
Major bleeding with ticagrelor
NS13
NS
NS
NS
NS
0
K-M
esti
ma
ted
ra
te (
% p
er
ye
ar)
PLATO major bleeding
1
2
3
4
5
6
7
8
9
10
12
11
TIMI major bleeding
Red cell transfusion
PLATO life-threatening/fatal bleeding
Fatal bleeding
11.611.2
7.9 7.7
8.9 8.9
5.8 5.8
0.3
TicagrelorClopidogrel
Wallentin L, et al. N Engl J Med 2009;361:1045-105722
![Page 23: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/23.jpg)
Ticagrelor
Adenosine
Clopidogrel
Prasugrel
Dipyridamol
23
![Page 24: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/24.jpg)
Dyspnoea with ticagrelor
• Dyspnoea in patients receiving ticagrelor is usually mild or moderate in intensity and often resolves without the need for treatment discontinuation2,3
• Dyspnoea during ticagrelor treatment does not appear to be associated with any differences in efficacy or bleeding-related clinical outcomes compared with clopidogrel2
† Most episodes of dyspnoea lasted less than a week
Dyspnoea† (%) Ticagrelor(n=9,235)
Clopidogrel(n=9,186)
p value
Any 13.8 7.8 < 0.001
With discontinuation of treatment 0.9 0.1 < 0.001
1. Wallentin L, et al. N Engl J Med 2009;361:1045-1057; 2. Storey RF, et al. Poster presented at European Society of Cardiology,
Stockholm, Sweden, 28 August–1 September 2010; 3. Ticagrelor. Summary of product characteristics. 201024
![Page 25: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/25.jpg)
ESC guidelines - STEMI
Steg G et al. European Heart Journal 2012;33:2569-2619 25
![Page 26: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/26.jpg)
ESC guidelines - NSTEMI
Hamm CW et al. European Heart Journal 2011;32:2999-3054 26
![Page 27: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/27.jpg)
ESC guidelines – Stable CAD
Montalescot G et al. European Heart Journal 2013;34:2949-3003 27
![Page 28: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/28.jpg)
Duration of DAPT
• Controversial
• Currently, 1 year after ACS, 6 months after DES, 1 month after BMS
• Several trials have examined this: ARCTIC-Interruption1, SECURITY2, DAPT3.
• Conclusions:– High risk of bleeding, stop sooner
– High risk of ischaemia/thrombus, continue
– ?personalised risk score
281. Collet JP et al. Lancet 2014;384:1577-1585; 2. Colombo A et al. JACC 2014;64:2086-2097; 3. Mauri L et al. NEJM 2014;371:2155-2166
![Page 29: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/29.jpg)
NON-CARDIAC SURGERY POST-PCI
Ris
k o
f B
lee
din
g
Ris
k o
f T
hro
mb
osisHaemostatic
Balance
29
![Page 30: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/30.jpg)
Discontinuation of DAPT
• 14.4% stop 1 or 2 antiplatelets for at least 5 days in the first year post PCI
• Causes of discontinuation of DAPT– Bleeding events/invasive procedures (50%)
– Medical decision (32%)
– Patient decision (18%)
• Predictors of discontinuation– Renal impairment
– Previous haemorrhage
– Peripheral vascular disease
Ferreira-Gonzalez et al. Circulation 2010 30
![Page 31: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/31.jpg)
Eisenberg MJ et al. Circulation 2009;119:1634-1642
Discontinuation of DAPT
31
![Page 32: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/32.jpg)
Stop or continue ...
Continuing Aspirin/DAPT
• Increased bleeding– Aspirin alone: 20%
– DAPT: 50%
• No increased mortality except in intracranial surgery
• Increased transfusion by 30%
• Background risk of MI
Withdrawing Aspirin/DAPT
• ?rebound effect
• Early stent thrombosis in up to 35%, with mortality of 20-40%, i.e. Increased peri-operative cardiac death rate 5-10x
• Poorer outcomes of peri-operative MI
MDT: Anaesthetists + Surgeons + Cardiologists + Patients32
![Page 33: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/33.jpg)
ESC recommendation
Windecker S et al. European Heart Journal 2014;35:2541-2619 33
![Page 34: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/34.jpg)
Timing is important: Ontario study
• N=8116, DES in 33%
• Overall event rate = 2.1% (intermediate risk)
Wijeysundera DN, et al. Circulation 2012;126(11):1355-6234
![Page 35: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/35.jpg)
ESC recommendation
Montalescot G et al. European Heart Journal 2013;34:2949-3003 35
![Page 36: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/36.jpg)
PACEMAKERS AND PERI-OPERATIVE MANAGEMENT
36
![Page 37: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/37.jpg)
Cardiac devices
• What type of device is it: pacemaker or defibrillator?
• ID card?
–Device manufacturer
–Model number
–Serial number
–Implanting hospital
–Follow-up hospital
–Date of implant
–Reason for implant
37
![Page 38: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/38.jpg)
What device is this?
38
![Page 39: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/39.jpg)
CRT trials
TRIAL NYHA LVEF (%) QRS (msec) COMMENTS
COMPANION 1(2004)
III-IV ≤35% ≥120 ~20% reduction in all cause mortality or hospitalization from any cause
CARE-HF 2
(2005)III-IV ≤35% ≥120 RRR of death 37%
MADIT-CRT 3
(2009)I-II ≤30% ≥130 CRT-D: 34% reduction in all-cause
mortality and heart failure events vs. ICD
RAFT 4 (2010) II-III ≤30% ≥120 CRT-D: 25% reduction in all-cause mortality and hopitalisations vs. ICD
ECHO-CRT 5
(2013)III-IV ≤35% <130 +
dyssynchronyCRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality
1. Bristow MR, et al. N Engl J Med 2004;350(21):2140-50; 2. Cleland JGF, et al. N Engl J Med 2005;352:1539-49; 3. Moss AJ, et al. N Engl J Med 2009;361:1329-38; 4. Tang
ASL, et al. N Engl J Med 2010;363(25):2385-95; 5. Ruschitzka F, et al. N Engl J Med 2013;369:1395-140539
![Page 40: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/40.jpg)
Practically...
• Get device checked if possible
–Confirm in working order
–Check if pacing dependent
–Programming of device if necessary
• Monitoring
• Resuscitation/pacing equipment
• Magnet?
40
![Page 41: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/41.jpg)
What’s new in EP?
Leadless pacemaker Subcutaneous ICD
41
![Page 42: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/42.jpg)
What’s new in EP?
Telemonitoring Vagal nerve stimulation
42Hindricks G et al. Lancet 2014;384:583-590
![Page 43: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/43.jpg)
ATRIAL FIBRILLATION AND STROKE PREVENTION
43
![Page 44: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/44.jpg)
AF and stroke
• AF is associated with a 5-fold higher stroke risk overall1
• Without prevention, approximately 1 in 20 patients will have a stroke each year3
• Responsible for nearly a third of all strokes,5 and the leading cause of embolic stroke6
1. Savelieva I et al. Ann Med 2007;39:371–91; 2. ACC/AHA/HRS focused update guidelines: Fuster V et al. Circulation 2011;123:e269–357; 3. Atrial Fibrillation Investigators. Arch Intern
Med 1994;154:1449–57; 4. Carlson M. Medscape Cardiol 2004;8; available at http://www.medscape.org/viewarticle/487849; accessed Feb 2010; 5. Hannon N et al. Cerebrovasc Dis
2010;29:43–9; 6. Emmerich J et al. Eur Heart J 2005;7(Suppl C):C28–3344
![Page 45: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/45.jpg)
Strokes in AF are worse!
• Compared with other causes, stroke in AF:
–Is usually more severe1
–Is more likely to be disabling:2
–Has double the post-stroke mortality rate3
1. Savelieva I et al. Ann Med 2007;39:371–91; 2. Dulli DA et al. Neuroepidemiology 2003;22:118–23; 3. Benjamin EJ et al. Circulation 1998;98:946–52 45
![Page 46: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/46.jpg)
Source of thromboembolism in AF
The left atrial appendage is the source of thromboemboli in ~80% of AF patients with stroke
46
![Page 47: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/47.jpg)
47http://www.nice.org.uk/nicemedia/live/14573/68045/68045.pdf
![Page 48: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/48.jpg)
DAPT vs. warfarin
RR = 1.72 AR ↑= 1.0%
48
![Page 49: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/49.jpg)
Stroke prevention: CHA2DS2-VASc
• CCF 1
• Hypertension 1
• Vascular disease 1
• Diabetes 1
• Stroke or TIA 2
• Female gender 1
• Age ≥ 65 1 or
• Age ≥ 75 2
0: No anticoagulation
≥1 (Men) or ≥2 (Women): Anticoagulate
49Lip GY et al. Chest 2010;137(2):263-72, http://www.nice.org.uk/nicemedia/live/14573/68045/68045.pdf
![Page 50: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/50.jpg)
Bleeding risk
• HAS-BLED• Hypertension 1• Abnormal renal or liver function 2• Stroke 1• Bleeding history 1• Labile INR 1• Age > 65 1• Drugs or alcohol 2
• 3+: High risk for bleeding with warfarin
50Pisters R. Chest. 2010 Nov;138(5):1093-100
![Page 51: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/51.jpg)
Warfarin therapeutic window
Relationship between clinical events and INR intensity
ICH=intracranial hemorrhage
INR=international normalized ratio
1. Hylek EM et al. Ann Intern Med 1994;120:897-902; 2. Hylek EM et al. N Engl J Med 1996;335:540-54651
![Page 52: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/52.jpg)
Time in therapeutic range (TTR)
0 500 1000 1500 2000
Survival to stroke (days)
0.6
0.7
0.8
0.9
1.0
Cu
mu
lati
ve s
urv
ival
71–100%
Warfarin group
61–70%51–60%41–50%31–40%<30%Non warfarin
Morgan CL et al. Thrombosis Research 2009;124:37–41 52
![Page 53: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/53.jpg)
Alternatives to warfarin (NOACs)
Factor Xa inhibitors:ApixabanRivaroxabanEdoxaban
Direct Thrombin inhibitor:Dabigatran
53
![Page 54: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/54.jpg)
NOACs vs. warfarin
SSE* vs. Warfarin(ITT population)
ARR HR
D150 0.60 0.65 (0.52-0.81)
D110 0.17 0.90 (0.74-1.10)
Rivaroxaban 0.30 0.88 (0.75-1.03)
Apixaban 0.33 0.79 (0.66-0.95)
Haemorrhagic stroke vs. Warfarin
ARR HR
D150 0.28 0.26 (0.14-0.49)
D110 0.26 0.31 (0.17-0.56)
Rivaroxaban 0.18 0.59 (0.37-0.93)
Apixaban 0.23 0.51 (0.35-0.75)
Connolly et al, N Eng J Med 2009; 361 and Vol. 363 No.19; Patel et al, N Eng J Med 2011; 365; Granger et al, N Eng J Med 2011; 365
*SSE (Stroke, Systemic Embolism)
![Page 55: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/55.jpg)
NOACs vs. warfarin
IntracranialBleeding
ARR HR
D150 0.44 0.41 (0.28-0.06)
D110 0.53 0.30 (0.19-0.45)
Rivaroxaban 0.20 0.67 (0.47-0.93)
Apixaban 0.47 0.42 (0.30-0.58)
Connolly et al, N Eng J Med 2009; 361 and Vol. 363 No.19
Patel et al, N Eng J Med 2011; 365 Granger et al, N Eng J Med 2011; 365
Major Bleeding ARR HR
D150 0.25 0.93 (0.81-1.07)
D110 0.70 0.80 (0.70-0.93)
Rivaroxaban -0.20 1.04 (0.90-1.20)
Apixaban 0.96 0.69 (0.60-0.80)
![Page 56: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/56.jpg)
NOACs
Pros
• No frequent blood tests
• Beneficial in all bleeding risks
• All reduce ICH
Cons
• Caution in patients with elevated bleeding risk and prior to invasive therapy
• Renal and liver impairment
• Drug interactions
• Can’t monitor
• Cost
• NOT licensed in valvular AF or prosthetic valves
56
![Page 57: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/57.jpg)
Practical issues
• Dabigatran prolongs TT but not aPTT• Rivaroxaban and apixaban prolong aPTT (slightly) but
not TT• PT/INR is not helpful• Need to stop at least 5 doses before major surgery• If major bleeding:
– Maintained diuresis– Supportive treatment with blood/platelet
transfusion– Consider PCC (e.g. FEIBA, Beriplex)– Consider haemodialysis (remove 40-60% in 4 hrs)
57
![Page 58: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/58.jpg)
OOHCA WITHOUT ST ELEVATION
58
![Page 59: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/59.jpg)
Meta-analysis
NO RANDOMISED STUDIES!
Larsen JM and Ravkilde Jl. Resuscitation 2012;83:1427-143359
![Page 60: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/60.jpg)
Consensus document
Noc M, et al. Eurointervention 2014;10:31-3760
![Page 61: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/61.jpg)
Advice…
• VF: ischaemia?
• LBBB: ischaemia?
• ACS treatment
• Echo if unsure
61
![Page 62: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/62.jpg)
WHAT’S NEW IN HEART FAILURE?
62
![Page 63: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/63.jpg)
The headlines: PARADIGM
63McMurray JJV, et al. NEJM 2014;371(11):2993-1004
![Page 64: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/64.jpg)
The headlines: SERVE-HF
64Cowie MR, et al. NEJM 2015;373(12):1095-105
![Page 65: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/65.jpg)
The headlines: CONFIRM-HF
65Ponikowski P, et al. EHJ 2015;36(11):657-68
![Page 66: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/66.jpg)
The headlines: EMPA-REG OUTCOME
66Zinman B, et al. NEJM 2015;373(22):2117-28
![Page 67: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/67.jpg)
2016 ESC Guidelines
• Recommendations on the diagnostic criteria for HF with reduced EF (HFrEF), HF with mid-range EF (HFmrEF) and HF with preserved EF (HFpEF)
• A new algorithm for the diagnosis of HF in the non-acute setting based on the evaluation of HF probability
• Recommendations aimed at prevention or delay of the development of overt HF or the prevention of death before the onset of symptoms
• Indications for the use of the new compound sacubitril/valsartan, the first in the class of angiotensin receptor neprilysin inhibitors (ARNIs)
• Modified indications for cardiac resynchronization therapy (CRT)• The concept of an early initiation of appropriate therapy going• A new algorithm for a combined diagnosis and treatment
approach of acute HF
67
![Page 68: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/68.jpg)
Cardioprotection
No ‘Conditioning’
Heart Ischaemia Reperfusion‘Conditioned’
Ischaemic
Postconditioning
2003
< 1min
Ischaemic
Preconditioning
1986
0 to 3 hrs
Remote
Ischaemic
Conditioning
Pharmacological
conditioning
68
![Page 69: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/69.jpg)
ERICCA
69Hausenloy D, et al. NEJM 2015;373(15):1408-17
![Page 70: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/70.jpg)
Thank you
![Page 71: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/71.jpg)
Summary
• Acute coronary syndromes & PCI
• Antiplatelet agents
• Pacemakers and peri-operative management
• Atrial fibrillation and stroke prevention
• OOHCA without ST elevation
• What’s new in heart failure – LCZ696, IV iron, SGLT-2 inhibitors
71
![Page 72: Cardiology Update - Infomed Research & Training Limited · Cardiology Update 11th Update for the General Anaesthetist, June 2017 1 Daniel Bromage NIHR Clinical Lecturer & Specialty](https://reader034.vdocument.in/reader034/viewer/2022050209/5f5b814faeff3460765aaffa/html5/thumbnails/72.jpg)
• EMPA-REG
• SERVE-HF
72